Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast Inc (MED) provides investors and stakeholders with centralized access to official company announcements and market-moving developments. This resource aggregates all press releases, financial disclosures, and strategic updates from the clinical nutrition leader known for its OPTAVIA® coaching programs and evidence-based weight management solutions.
Users will find chronological updates covering earnings reports, product innovations, leadership changes, and operational milestones. The curated collection serves as both historical record and strategic tool for tracking MED's position in the $250B+ global wellness industry.
Key content categories include quarterly financial results, clinical study publications, partnership announcements, and regulatory filings. All materials are sourced directly from Medifast's investor relations team to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of MED's business trajectory, with updates organized to highlight material developments affecting long-term growth in the health solutions sector.
Medifast (NYSE: MED) announced a $100 million accelerated share repurchase (ASR) program with JPMorgan Chase to buy back approximately 600,000 shares, representing 5% of its outstanding stock. This move aims to enhance shareholder value and reflects the company's confidence in its growth strategy. Medifast plans to use available cash and borrowings for the ASR, with a remaining 1.4 million shares authorized for repurchase. The final settlement of the ASR will occur in Q3 2022, as the company continues to generate strong cash flow and invests in technology and product innovation.
Medifast has inaugurated the Medifast Product Innovation Center in Baltimore on May 10, 2022, to accelerate innovation and support its rapid growth in the $230 billion health and wellness market. The facility includes advanced office, lab, and pilot plant spaces, aimed at enhancing R&D, packaging engineering, and quality assurance. CEO Dan Chard highlighted that the company's revenue has doubled twice in five years, emphasizing the center's role in developing scientifically-backed products for its OPTAVIA program and expanding into new health segments.
Medifast, Inc. (NYSE: MED) reported a remarkable 22.6% increase in revenue to $417.6 million for Q1 2022, driven by a 21.7% rise in active OPTAVIA Coaches to 63,900. Net income grew 1.7% to $41.8 million, with earnings per share (EPS) at $3.59, a 3.8% increase. The company raised its annual revenue guidance to between $1.78 billion and $1.84 billion and adjusted full-year EPS expectations to $14.60 to $16.05. Despite growing expenses and lower gross profit margin, Medifast’s strong balance sheet and operational metrics indicate robust business health.
Medifast, Inc. (NYSE: MED) will announce its financial results for Q1 ended March 31, 2022, on May 2, 2022, after market close. A conference call with CEO Dan Chard and CFO Jim Maloney will follow at 4:30 p.m. ET, accessible via Medifast's investor relations website. Interested parties can also join via telephone at (855) 560-2579. The playback of the call will be available from May 2 through May 9, 2022. Medifast emphasizes its commitment to health and wellness through its OPTA VIA community, which has positively impacted over 2 million lives.
Medifast has declared a $1.64 quarterly cash dividend for its shareholders, payable on May 9, 2022. This dividend will be distributed to stockholders recorded as of the close of business on March 29, 2022. The company emphasizes its intention to maintain a quarterly dividend program, subject to the Board of Directors' discretion and evaluation based on relevant factors.
Medifast reported robust financial results for Q4 and FY 2021, with a 42.6% increase in quarterly revenue to $377.8 million and a 63.2% rise in annual revenue to $1.526 billion. Net income surged 21.5% in Q4 to $34.0 million and 59.5% for the year to $164.0 million. Diluted EPS reached $2.91 in Q4, up 23.3%, and $13.89 annually, an increase of 60.0%. However, gross profit margin fell 1.5% percentage points due to inflation impacts. The company expects FY 2022 revenue between $1.72 billion and $1.79 billion.
Medifast, Inc. (NYSE: MED) will announce its financial results for Q4 and full year 2021 on February 23, 2022, after market close. The conference call will start at 4:30 p.m. ET, featuring CEO Dan Chard and CFO Jim Maloney discussing the results. This announcement is crucial for investors as it provides insights into the company's financial performance and future outlook. The call can be accessed via Medifast's website, and there will be a playback option available until March 2, 2022. For more information, visit MedifastInc.com.
Medifast, Inc. (NYSE: MED) announced that CEO Dan Chard and CFO Jim Maloney will present at the 2022 ICR Conference on January 11, 2022, at 2:30 p.m. ET. The presentation will be live-streamed on Medifast's Investor Relations website and archived until January 25, 2022. Medifast is recognized for its OPTAVIA® health and wellness community, emphasizing lifelong transformation through healthy habits. The company has received accolades such as FORTUNE's 100 Fastest-Growing Companies and was named one of Forbes' 100 Most Trustworthy Companies in America.
Medifast (NYSE: MED) released a survey indicating that only 10% of U.S. adults successfully maintain their New Year's resolutions, with 47% breaking theirs within the first month. The intention to set resolutions has dropped to 44% in 2022 from 50% in 2021, attributed mainly to lack of motivation. The survey shows a shift towards manageable lifestyle changes; 58% of respondents prefer gradual habit changes, and 66% favor smaller daily adjustments over quick diets. Medifast's OPTAVIA® supports this approach through community and coaching.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
